MedicinePharmacokineticsSurgeryHepatologyRenal PathophysiologyRenal PharmacokineticsHepatic ImpairmentLiver DiseaseLiver TransplantationRenal DiseaseTransplant PharmacokineticsTransplant PharmacologyLiver Transplant RejectionOrgan Dysfunction After TransplantationPharmacokinetics In Liver TransplantationPharmacokinetics In Transplantation
FK 506 is a potent immunosuppressant agent which has undergone extensive in vitro and animal studies since its discovery in 1983.1–3 Since the first International Workshop on FK 506 in 1987, growing excitement has surrounded the development of an agent which is 100 times more potent than CyA.1 The major limitation of CyA has been the almost universal development of nephrotoxicity, leading to renal failure and the need for dialysis in some patients.4,5 The development of an agent which is more potent than CyA and which is less nephrotoxic would be a major advance in organ transplantation. We report our preliminary results on renal function and associated factors, using FK 506 as the major immunosuppressant in humans after liver transplantation.
8
FK 506 FOR LIVER, KIDNEY, AND PANCREAS TRANSPLANTATION
ThomasE. Starzl, John J. Fung, Raman Venkataramman et al. · The Lancet · 1989 · 1.1K citations
Medicine, Pharmacokinetics, Surgery +12
Acute and Chronic Renal Failure in Liver Transplantation
Jerry McCauley, David H. Van Thiel, Thomas E. Starzl et al. · The Nephron journals/Nephron journals · 2008 · 196 citations · Full text
Medicine, Nephrology, Surgery +12
A highly sensitive method to assay FK-506 levels in plasma.
Kyoichi Tamura, Minoru Kobayashi, Kazuhiko Hashimoto et al. · PubMed · 1987 · 148 citations
A. Zeevi, R Duquesnoy, G Eiras et al. · PubMed · 1987 · 92 citations · Full text